{
  "id": "propofol_pharmacology_001",
  "updatedAt": "2026-02-17T00:00:00Z",

  "domain": "pharmacology",
  "topicTagIds": ["iv_anaesthetics", "pharmacokinetics", "pharmacodynamics"],
  "caseId": null,
  "slotType": "any",
  "caseOrder": 0,

  "demographics": {
    "patientAgeGroup": "adult",
    "patientGender": "male"
  },

  "stem": "Dr. {{surname}}, tell me about propofol.",

  "prompts": [
    {
      "tier": "recall",
      "text": "Can you describe the basic pharmacology of propofol?",
      "expectedKeyFacts": [
        "2,6-diisopropylphenol",
        "Presented as 1% or 2% lipid emulsion (soya bean oil, egg lecithin, glycerol)",
        "pKa 11 — virtually entirely un-ionised at physiological pH",
        "Highly protein-bound (~98%)",
        "GABA-A receptor agonist"
      ],
      "timeBudgetSec": 60
    },
    {
      "tier": "mechanism",
      "text": "How does propofol produce unconsciousness? And can you describe its pharmacokinetics?",
      "expectedKeyFacts": [
        "Enhances GABA-A mediated chloride conductance — neuronal hyperpolarisation",
        "Rapid onset (one arm-brain circulation time, ~30s)",
        "Three-compartment model",
        "Initial rapid distribution (t½α ~2-4 min)",
        "Elimination half-life 4-12 hours but context-sensitive half-time is short",
        "Hepatic metabolism (glucuronidation) + extrahepatic metabolism (lungs)",
        "Clearance exceeds hepatic blood flow — extrahepatic sites confirmed"
      ],
      "timeBudgetSec": 90
    },
    {
      "tier": "application",
      "text": "How would you modify your propofol dose in an elderly patient with cardiac failure? Why?",
      "expectedKeyFacts": [
        "Reduce induction dose (1-1.5 mg/kg vs 2-2.5 mg/kg)",
        "Slower arm-brain circulation — delayed onset, risk of stacking doses",
        "Reduced cardiac output prolongs redistribution",
        "Reduced protein binding in elderly — higher free fraction",
        "Exaggerated cardiovascular depression — hypotension, reduced SVR"
      ],
      "timeBudgetSec": 90
    },
    {
      "tier": "evaluation",
      "text": "A colleague asks why you use propofol rather than thiopentone for a patient requiring a short procedure. How would you justify your choice?",
      "expectedKeyFacts": [
        "Propofol: shorter context-sensitive half-time — faster recovery",
        "Less hangover effect, clear-headed recovery",
        "Antiemetic properties — advantageous for day surgery",
        "Suppresses airway reflexes — better for LMA insertion",
        "Thiopentone: longer recovery, no antiemetic effect, cumulative with repeated doses",
        "Acknowledge thiopentone advantages: more haemodynamically stable at induction, useful in specific contexts (status epilepticus)"
      ],
      "timeBudgetSec": 60
    }
  ],

  "rescuePrompt": "Perhaps you could tell me about the side effects of propofol — what do you see clinically when you give an induction dose?",

  "keyFacts": [
    "2,6-diisopropylphenol in lipid emulsion",
    "GABA-A receptor agonist",
    "Rapid onset, rapid offset due to redistribution",
    "Three-compartment pharmacokinetic model",
    "Context-sensitive half-time remains short even after prolonged infusion",
    "Hepatic and extrahepatic metabolism",
    "Cardiovascular depression — reduced SVR, negative inotropy",
    "Respiratory depression — apnoea common at induction",
    "Suppresses airway reflexes",
    "Antiemetic at sub-hypnotic doses",
    "Pain on injection — lipid formulation reduces but doesn't eliminate",
    "Propofol infusion syndrome (PRIS) with prolonged high-dose infusions"
  ],

  "scoringGuidance": {
    "pass_plus": "Structured pharmacological approach, explains three-compartment model, context-sensitive half-time concept, discusses clinical dose adjustments with reasoning, balanced comparison with alternatives",
    "pass": "Correct mechanism (GABA-A), describes rapid onset/offset, aware of cardiovascular depression, can modify dose for elderly, knows basic advantages over thiopentone",
    "borderline": "Knows propofol is an IV anaesthetic and causes hypotension but mechanism unclear, vague on pharmacokinetics, dose adjustment without reasoning",
    "fail": "Cannot describe mechanism of action, unaware of significant cardiovascular effects, no understanding of dose modification in vulnerable patients"
  },

  "author": "SimViva Team",
  "provenance": {
    "generatedBy": "Claude 3.5 Sonnet",
    "generatedAt": "2024-02-18T10:00:00Z",
    "promptVersion": "v1.0.0",
    "sourceMaterial": ["BJA_Propofol_Pharmacology_2018", "RCoA_Propofol_Guideline"],
    "validation": {
      "reviewedBy": "Dr. Sarah Admin, FRCA",
      "reviewedAt": "2024-02-19T14:30:00Z",
      "status": "approved",
      "accuracy": 1.0,
      "concordance": 0.95,
      "insight": 0.8,
      "notes": "Excellent clinical context on elderly dosing."
    }
  },
  "furtherReading": [
    "https://doi.org/10.1093/bjaceaccp/mkt039"
  ],
  "isActive": true
}
